Central nervous system lesions in von Hippel-Lindau syndrome

H P H Neumann, H R Eggert, R Scherermet, M Schumacher, M Mohadjer, A K Wakhloo, B Volk, U Hettmannsperger, P Riegler, P Schollmeyer, O Wiestler

Abstract

CNS manifestations were studied in 97 gene carriers of von Hippel-Lindau syndrome (HLS). Haemangioblastomas of the CNS were found in 43 patients (44%), 23 females and 20 males. The mean age at diagnosis was 39 years (12–73 years). A total of 93 haemangioblastomas were detected of which 74% were intracranial and 26% were located in the spinal cord; 75% were predominantly cystic and 25% presented as solid lesions. Multiple lesions were found in 42% of HLS-associated haemangioblastomas, but in none of 51 patients with CNS haemangioblastoma without HLS. Haemangioblastoma was the cause of death in 82% of patients with HLS. Although microsurgery has considerably improved post-operative results, multifocal tumour development and recurrence remain a serious problem in the clinical management of HLS gene carriers.

(Von Hippel-Lindau syndrome (HLS) is a familial disorder with an autosomal dominant pattern of inheritance. Afflicted patients develop a variety of tumours in different organs. Common lesions are angiomatosis of the retina, CNS haemangioblastomas, renal cysts and cancer, pancreatic cysts, pheochromocytoma and epididymal cystadenoma. Although eponymous and the frequent lesion associated with the syndrome, Lindau’s tumour—thecystic haemangioblastoma of the cerebellum—is not found in every individual afflicted, nor is it the only neuropathological lesion in HLS patients. We have studied a large series of HLS patients to evaluate the prevalence and location of CNS lesions, together with the morbidity, mortality and occurrence of lesions associated with HLS in other organs.

Methods

This study included 97 patients who were confirmed gene carriers for von Hippel-Lindau syndrome. Carriers were identified as being affected members of known HLS kindreds or by detecting additional manifestations of the syndrome, or both. Since 1976, all patients presenting with CNS haemangioblastoma at our institute were systematically registered and examined. For these patients, a screening programme (table 1) for HLS was developed and used for a prospective study. All first-degree relatives of afflicted individuals were included. For this purpose, an extensive pedigree analysis was performed, and patients with CNS lesions treated at other hospitals were also entered in the study.

CNS lesions were confirmed histopathologically using biopsy or necropsy material, by conventional staining methods. Immunohistochemical staining techniques were used in selected cases. The few CNS lesions that had not been surgically investigated, were classified as haemangioblastomas because of a history of previous haemangioblastoma, multifocal manifestations, a characteristic appearance in gadolinium-enhanced MRI and a typical location in the posterior cranial fossa or spinal canal.

Diagnostic imaging has been by CT and angiography since 1976, MRI since 1987, and contrast-enhanced MRI (using gadolinium-DTPA) since 1989.

Results

CNS HAEMANGIOBLASTOMA

CNS haemangioblastomas were found in 43 gene carriers from 30 families. There were 23 females and 20 males; the age at diagnosis ranged from 12–60 years (average 33–9). Of the 21 patients still alive, 15 are female, 6 are male, with an age range of 19–73 years (average 40). Of the 22 patients who died, 9 were female, 13 were male, with an age range of 12–60 years (average 39). In 82% of these patients, haemangioblastoma was the cause of death. After 1980, however, only one of 14 HLS carriers and none of 43 with sporadic haemangioblastomas died because of CNS haemangioblastoma. This suggests that modern neuroimaging techniques and microsurgery have considerably improved the prognosis of these patients.

The total number of haemangioblastomas observed in these patients was 93, of which 73% were located in the posterior fossa, 26% in the spinal canal, and 1% was supratentorial.
Sixty seven haemangioblastomas were identified by biopsy, nine were found at necropsy, and 17 were diagnosed by neuroradiology. Seventy-five per cent of the tumours were cystic and 25% were solid; in the posterior fossa, 86% were cystic and in the spine, 46%. The supratentorial lesion was solid.

Histopathology showed characteristic haemangioblastomas (World Health Organisation grade I) in all cases. No significant difference in histopathological appearance was noted between sporadic haemangioblastomas and those associated with HLS.

Multifocal haemangioblastomas occurred in 18 patients (42%); of these, eight have died. At the time of the original diagnosis, multiple lesions were found in nine (21%). Five patients with haemangioblastoma had surgery twice; two, three times; one, four times, and one, six times (fig 1).

In contrast, none of 51 patients (mean age 47 years, 18 female, 33 male) presenting with a sporadic CNS haemangioblastoma during the last 13 years developed multiple lesions; all these subjects underwent screening for HLS according to the programme in table 1. Their mean age was 47.2 years and is significantly different (p < 0.05) from the mean age of the HLS carriers (33.9) years.

Tumours were surgically removed when signs of increased intracranial pressure or focal neurological deficits occurred or neuroradiological examination revealed evidence for rapid growth. When MRI scans showed lesions compatible with CNS haemangioblastoma in 14 patients, clinical follow-up revealed no signs of tumour progression. Surgery has not been performed on these patients so far.

Post-operative gadolinium-enhanced MRI was conducted annually in cases with a solitary tumour, and at six-monthly intervals in patients with multifocal lesions. Since the introduction of microsurgery post-operative outcome has been generally good. Of 19 patients, one died of multilocular haemangioblastomas, one had residual paraparesis and one had quadriplegia caused by spinal lesions. The other patients recovered completely.

Polycythaemia, a well-documented feature in CNS haemangioblastoma was present in only five of 43 cases (12%).

Metastases
Metastatic involvement of the CNS occurred in two HLS patients. The first was a 42 year old woman with a history of a renal cell carcinoma. Two years after nephrectomy this patient experienced the symptoms of Brown-Sequard syndrome, caused by a mass in the D4-region (fig 2a). Histopathology disclosed metastatic renal cell cancer. To distinguish between clear cell carcinoma and haemangioblastoma, immunocytochemical reactions were carried out with antibodies to the pan-epithelial antigen Lu-5, a marker for cells of epithelial origin which is not expressed in haemangioblastomas. This reaction was strongly positive, confirming the diagnosis of metastatic carcinoma (fig 2b). The second was a 60 year old woman with bilateral retinal angiomatosis and a long history of maligestion and malabsorption who developed severe pneumonia and died. Major findings at necropsy included islet-cell carcinoma of the pancreas with metastases to the liver, the cerebellum and the dura mater, and renal cell cancer.
Differential diagnosis of CNS haemangioblastoma and metastatic renal cell carcinoma

The distinction between CNS haemangioblastoma and metastatic renal cell carcinoma can pose a major histopathological problem. To differentiate these two neoplasms, reticulin impregnation and antibodies to keratin-associated antigens were used. We have encountered three cases which, on the basis of retrospective histopathological and immunocytochemical analyses, had to be reclassified (fig 3).

Incidence of CNS lesions in von Hippel-Lindau syndrome

In the present study, 44% of 97 HLS gene carriers had CNS haemangioblastomas. Other HLS manifestations occurred as follows: retinal angiomatosis in 44% (19 of 43), renal cysts, renal cancer or both in 47% (20 of 43), phaeochromocytoma in 5% (2 of 43), pancreatic cysts in 30% (13 of 43) and epididymal cystadenoma in 15% (3 of 20). Nine patients (21%) with CNS haemangioblastoma did not present with additional manifestations of the syndrome at the time of initial diagnosis.

In 56% of HLS gene carriers, no CNS haemangioblastoma was found. However, only 74% of these patients were examined by cranial CT, MRI or postmortem neuropathological analysis; the remaining patients had a normal neurological status. In seven affected families, CNS haemangioblastoma was not found among the features of the syndrome.

Discussion

The von Hippel-Lindau syndrome is an autosomal dominant inherited disorder in which sufferers are prone to develop cancer. Recent data indicate that HLS is more common than previously anticipated. The prevalence is in the range of 1:40 000–1:50 000.7 Non-neurological lesions, which contribute significantly to the morbidity and mortality of affected patients, include angiomatosis of the retina, renal cancer and phaeochromocytoma. The classic manifestations of HLS in the CNS are haemangioblastomas8 most of which are located in the posterior fossa but these tumours may also be found in other regions of the CNS. The incidence of haemangioblastoma was 21%, 53%, 57% and 72% respectively, reported in the previously published studies on large kindreds5 or small series of families with HLS.8,9 In the present series, CNS haemangioblastoma was found in 44% of the HLS gene carriers.

Interestingly, we have observed several families without a single instance of CNS haemangioblastoma. The genetic basis for the pattern of the manifestations in different kindreds is, at present, unknown.10

Haemangioblastomas of the CNS are of prognostic significance, as they tend to induce the formation of expanding cysts which may cause life-threatening complications and often require emergency treatment. Cerebellar haemangioblastomas were the major cause of death in 82% of the patients in the present series; similar figures have been reported by others.7 This manifestation is, therefore, of critical importance for the clinical management of HLS patients. Early detection may improve the prognosis of affected patients significantly. To identify asymptomatic carriers and early lesions, we have introduced a standard screening program for patients at risk for HLS (table 1). In addition, genetic linkage analysis with RFLP probes covering the HLS locus on chromosome 3p will provide an opportunity for presymptomatic diagnosis of affected individuals.10,11 Screening for CNS lesions should start at the age of 10 years, as our youngest patient with haemangioblastoma was 12 and the youngest patient reported in literature was only 11 years old.9

Modern imaging techniques such as MRI scanning and gadolinium-EDTA enhanced MRI (fig 1) have considerably improved the diagnostic repertoire for early detection of small CNS lesions12 and for the demonstration of multiple haemangioblastomas, a feature
encountered in 42% of our patients and in 50% in a recently published study on HLS-associated haemangioblastomas.

The development of multifocal CNS haemangioblastomas appears to be a distinctive feature of HLS, as there was no multiplicity in 51 instances of sporadic intracranial haemangioblastoma. Age was also an important factor: HLS patients with CNS haemangioblastoma became symptomatic about 15 years earlier than patients with sporadic haemangioblastoma.15 Other parameters, including location of the tumours and gross or histopathological appearance, were not found to be significantly different between the two groups. We have previously evaluated a series of 63 consecutive CNS haemangioblastomas treated at this institute, 19% of which were found to be associated with HLS.16 Additional manifestations of HLS should be excluded, therefore, in every patient presenting with intracranial or spinal haemangioblastoma.

Follow-up examinations however, are required in these patients. In our series, 21% had not yet developed additional manifestations of the syndrome at the time of neurosurgical intervention. In 47% of the HLS patients with haemangioblastoma, non-neurological lesions were identified only during the screening program outlined in Table I. This indicates that CNS haemangioblastomas are the initial manifestation of the syndrome in a large fraction of HLS patients.

Other CNS manifestations are uncommon. Metastatic renal cell carcinoma was found in the spinal cord of one patient (Fig. 2). Since both CNS haemangioblastoma and renal cancer represent common features of HLS, the distinction between them can pose a problem. Difficulties may also be encountered in the histopathological differentiation of cerebellar haemangioblastoma and clear cell carcinoma of the kidney. Cytologically, these tumours may be almost indistinguishable. Immunohistochemical reactions with antibodies to epithelial marker antigens, such as cytokeratins or the pan-epithelial antigen Lu-5 may be required to confirm the diagnosis.14 In one of our patients metastatic islet-cell carcinoma of the brain was identified at necropsy. This lesion has only occasionally been described in HLS patients.17 18 15 16

Three members of HLS kindreds of our study presented with ependymoma, astrocytoma and metastatic carcinoid of the brain. As additional features of HLS could not be demonstrated, however, the association with HLS is uncertain. Reports in the literature of atypical CNS neoplasms in patients at risk of HLS, are extremely rare. In order to confirm a potential relationship with HLS, such tumours should be evaluated for loss or inactivation of the HLS tumour suppressor gene as soon as the gene is cloned and appropriate reagents become available.19 20

In conclusion, CNS haemangioblastomas constitute a major manifestation of HLS, are found in about 50% of gene carriers, tend to develop 15 years earlier compared with sporadic haemangioblastoma, and have a striking tendency for multiple occurrence in HLS patients. Although microsurgical techniques have considerably improved the postoperative outcome in patients with CNS haemangioblastoma, multifocal tumour development and recurrence are still serious problems. Whether novel therapeutic strategies, such as selective embolisation of feeding vessels, can overcome some of these problems remains to be determined.

Central nervous system lesions in von Hippel-Lindau syndrome.

H P Neumann, H R Eggert, R Scheremet, M Schumacher, M Mohadjer, A K Wakhloo, B Volk, U Hettmannsperger, P Riegler and P Schollmeyer

*J Neurol Neurosurg Psychiatry* 1992 55: 898-901
doi: 10.1136/jnnp.55.10.898

Updated information and services can be found at:
http://jnnp.bmj.com/content/55/10/898

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/